APA

Vreman R. A., de Ruijter A. S., Zawada A., Tafuri G., Stoyanova-Beninska V., O'Connor D., Naumann-Winter F., Wolter F., Mantel-Teeuwisse A. K., Leufkens H. G. M., Sidiropoulos I., Larsson K. & Goettsch W. G. (20210830). Assessment of significant benefit for orphan medicinal products by European regulators may support subsequent relative effectiveness assessments by health technology assessment organizations. : Drug discovery today.

Chicago

Vreman Rick A, de Ruijter Angela S, Zawada Anna, Tafuri Giovanni, Stoyanova-Beninska Violeta, O'Connor Daniel, Naumann-Winter Frauke, Wolter Franziska, Mantel-Teeuwisse Aukje K, Leufkens Hubert G M, Sidiropoulos Iordanis, Larsson Kristina and Goettsch Wim G. 20210830. Assessment of significant benefit for orphan medicinal products by European regulators may support subsequent relative effectiveness assessments by health technology assessment organizations. : Drug discovery today.

Harvard

Vreman R. A., de Ruijter A. S., Zawada A., Tafuri G., Stoyanova-Beninska V., O'Connor D., Naumann-Winter F., Wolter F., Mantel-Teeuwisse A. K., Leufkens H. G. M., Sidiropoulos I., Larsson K. and Goettsch W. G. (20210830). Assessment of significant benefit for orphan medicinal products by European regulators may support subsequent relative effectiveness assessments by health technology assessment organizations. : Drug discovery today.

MLA

Vreman Rick A, de Ruijter Angela S, Zawada Anna, Tafuri Giovanni, Stoyanova-Beninska Violeta, O'Connor Daniel, Naumann-Winter Frauke, Wolter Franziska, Mantel-Teeuwisse Aukje K, Leufkens Hubert G M, Sidiropoulos Iordanis, Larsson Kristina and Goettsch Wim G. Assessment of significant benefit for orphan medicinal products by European regulators may support subsequent relative effectiveness assessments by health technology assessment organizations. : Drug discovery today. 20210830.